Cervical cancer
Conditions
Interventions
HPV vaccine timely vaccination group (11-14 years old):Receive two doses of HPV16/18 bivalent vaccine at month 0 and month 6
HPV vaccine delayed vaccination group (11-14 years old):Administer two doses of HPV16/18 bivalent vaccine at 0 and 18 months
Cervical cancer screening group (Grouping based on whether or not HPV vaccine has been administered) (35-64 years old):None
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
Female
Age
11 Years to 64 Years
Inclusion criteria
Inclusion criteria: Aged 11-14 years and 35-64 years; never vaccinated with HPV vaccine; not used immunosuppressants, immunoglobulins, or blood products in the three months prior to vaccine monitoring sampling; local residents willing to participate in the study and able to cooperate with follow-up arrangements; no history of cervical cancer or cervical lesions (HPV uninfected in the vaccine group), and have not undergone cervical cancer screening for at least the past 3 years; not pregnant, at least 8 weeks postpartum; understand and voluntarily participate in the study, minors need informed consent from parents or guardians.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The IgG and IgA antibodies against HPV16/18 in serum;High-risk HPV Prevalence; | — |
Secondary
| Measure | Time frame |
|---|---|
| p16/Ki67;Adverse reactions ; | — |
Countries
China
Contacts
Public ContactLingyun Liang
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed